GlassScriptPhysician profile
Nickeisha Pilgrim
NPI 1740953876
$9,310.02
in general payments reported to CMS, 2019-2025
41 companies · $2,944 in 2025
The $2,944 reported for 2025 was more than what 96% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $482 · 2022: $1,008 · 2023: $1,849 · 2024: $3,028 · 2025: $2,944.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,820.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $851.06 | 2021-2024 | |
| Alexion Pharmaceuticals, INC. | $832.57 | 2023-2025 | Ultomiris, Strensiq |
| Teva Pharmaceuticals USA, INC. | $718.69 | 2024-2025 | Austedo Xr, Ajovy |
| Amgen INC. | $657.82 | 2025 | Tavneos, Repatha, Krystexxa |
| Novo Nordisk INC | $434.62 | 2022-2025 | Wegovy |
| Janssen Scientific Affairs, LLC | $404.43 | 2023-2024 | Xarelto |
| Coloplast Corp | $326.84 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $319.76 | 2021-2025 | Fasenra |
| Idorsia Pharmaceuticals US INC | $291.81 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $247.08 | 2023-2024 | |
| Amarin Pharma, INC. | $237.20 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $219.01 | 2025 | Neffy |
| Sumitomo Pharma America, INC. | $212.72 | 2024-2025 | Gemtesa |
| Janssen Pharmaceuticals, INC | $212.07 | 2023-2025 | Spravato |
| Boston Scientific Corporation | $207.71 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickeisha Pilgrim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.